Annovis Bio, Inc. Company Profile

Background

Overview

Annovis Bio, Inc. is a clinical-stage biotechnology company headquartered in Malvern, Pennsylvania, dedicated to developing transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The company's mission is to restore nerve cell function and improve cognitive and motor abilities in patients affected by these conditions. Annovis Bio is publicly traded on the NYSE under the ticker symbol ANVS.

Mission and Vision

Annovis Bio aims to address the challenges posed by neurodegenerative diseases by developing innovative treatments that enhance nerve cell communication and function. The company's vision is to improve patient outcomes and quality of life through the restoration of nerve cell homeostasis.

Industry Significance

The biotechnology industry, particularly in the realm of neurodegenerative diseases, is characterized by high unmet medical needs and significant research challenges. Annovis Bio's focus on restoring nerve cell function positions it as a key player in developing potential disease-modifying therapies for AD and PD.

Key Strategic Focus

Core Objectives

Annovis Bio is committed to advancing its pipeline of drug candidates targeting neurodegeneration, with a primary focus on AD and PD. The company's strategic objectives include:

• Advancing clinical trials for its lead product candidate, Buntanetap.

• Expanding research into other neurodegenerative disorders.

• Strengthening its leadership team to support growth and innovation.

Areas of Specialization

The company specializes in the development of small molecule therapies aimed at restoring nerve cell function by inhibiting neurotoxic proteins. This approach targets the underlying mechanisms of neurodegeneration, offering potential disease-modifying treatments.

Key Technologies Utilized

Annovis Bio employs proprietary technologies designed to:

• Inhibit the synthesis of neurotoxic proteins.

• Restore axonal transport and nerve cell homeostasis.

Primary Markets Targeted

The company's primary markets include:

• Patients diagnosed with Alzheimer's disease.

• Patients diagnosed with Parkinson's disease.

• Broader neurodegenerative disease patient populations.

Financials and Funding

Funding History

Annovis Bio has secured funding through various channels, including public offerings and private placements. Notable funding events include:

• May 2021: The company closed an underwritten public offering of 1,000,000 shares of common stock at a public offering price of $50.00 per share, resulting in gross proceeds of $50 million. The net proceeds were allocated primarily for general corporate purposes, including working capital, research and development, capital expenditures, and the completion of its planned Phase 3 clinical trial for ANVS401 in Alzheimer's disease patients with Down Syndrome.

• October 2025: Annovis Bio announced a $6 million registered direct offering of common stock.

Recent Financial Performance

As of September 30, 2025, Annovis Bio reported:

• Cash and Cash Equivalents: $15.3 million, an increase from $10.6 million as of December 31, 2024.

• Research and Development Expenses: $6.3 million for the three months ending September 30, 2025, compared to $2.7 million for the same period in 2024.

• General and Administrative Expenses: $1.1 million for the three months ending September 30, 2025, compared to $1.7 million for the same period in 2024.

• Net Loss Per Share: $0.37 basic and diluted for the three months ending September 30, 2025, compared to a net loss of $0.97 per share for the same period in 2024.

Pipeline Development

Key Pipeline Candidates

Annovis Bio's lead product candidate is Buntanetap, a small molecule therapy targeting neurodegeneration. The company is also developing ANVS405, targeting traumatic brain injury and stroke, and ANVS301, focusing on later stages of Alzheimer's disease and dementia.

Stages of Clinical Trials

• Buntanetap: Undergoing Phase 2/3 clinical trials for Alzheimer's disease and Phase 3 trials for Parkinson's disease.

• ANVS405: In Phase 2 and 3 clinical trials for traumatic brain injury and stroke.

• ANVS301: Completed Phase 1 clinical trials for later stages of Alzheimer's disease and dementia.

Target Conditions

The pipeline targets:

• Alzheimer's disease

• Parkinson's disease

• Traumatic brain injury

• Stroke

• Later stages of Alzheimer's disease and dementia

Anticipated Milestones

The company anticipates:

• Advancing Buntanetap through ongoing Phase 2/3 and Phase 3 trials.

• Progressing ANVS405 and ANVS301 through their respective clinical trial phases.

Technological Platform and Innovation

Proprietary Technologies

Annovis Bio's proprietary technologies focus on:

• Inhibiting the synthesis of neurotoxic proteins.

• Restoring axonal transport and nerve cell homeostasis.

Significant Scientific Methods

The company employs scientific methods that:

• Target multiple neurotoxic proteins simultaneously.

• Aim to restore nerve cell function and communication.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed in the available information, the company's focus on innovative drug development suggests potential integration of advanced technologies in its research and development processes.

Leadership Team

Key Executives

• Dr. Maria L. Maccecchini, Ph.D.: Founder, Chief Executive Officer, President, and Executive Director.

• Mark Patrick Guerin, C.M.A., CPA, CFM: Chief Financial Officer.

• Dr. Cheng Fang, Ph.D.: Senior Vice President of Research and Development.

• Eve M. Damiano, M.S., RAC: Senior Vice President of Regulatory Operations.

• Melissa Gaines: Senior Vice President of Clinical Operations.

• Blake Jensen, M.B.A.: Head of Quality.

• Hilda Maibach: Senior Vice President of Statistics.

Leadership Changes

In July 2024, Annovis Bio welcomed four new executives to strengthen its leadership team:

• Mark White: Appointed Chief Business Officer, bringing extensive experience from roles at Pfizer, Bracco, Abbott, and Bayer.

• Blake Jensen: Joined as Head of Quality, with a background in quality risk management and global audits.

• Melissa Gaines: Appointed Senior Vice President of Clinical Operations, contributing expertise in clinical trial management.

• Hilda Maibach: Joined as Senior Vice President of Statistics, offering experience in statistical analysis and clinical trial design.

Competitor Profile

Market Insights and Dynamics

The market for neurodegenerative disease therapies is characterized by high unmet needs and significant research challenges. Companies like Annovis Bio are competing to develop effective treatments for conditions such as Alzheimer's and Parkinson's diseases.

Competitor Analysis

Annovis Bio's competitors include other biotechnology firms focused on neurodegenerative diseases. For example, Annexon Biosciences (NASDAQ: ANNX) is developing therapeutics targeting neuroinflammation, while companies like Exelixis, Inc. (NASDAQ: EXEL) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) operate in the broader biotechnology sector.

Strategic Collaborations and Partnerships

Specific details about Annovis Bio's strategic collaborations and partnerships are not provided in the available information.